STOCK TITAN
  1. Home
  2. News
  3. CMPS

Compass Pathways Plc - CMPS STOCK NEWS

Welcome to our dedicated news page for Compass Pathways Plc (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Compass Pathways Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Compass Pathways Plc's position in the market.

News
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
Rhea-AI Summary
Compass Pathways plc announces the resignation of co-founders George Goldsmith and Ekaterina Malievskaia from the board of directors, with David Norton assuming the role of interim board chair. The company is conducting a global search for a new chair with expertise in biotechnology. George and Ekaterina leave a strong legacy with key achievements in obtaining regulatory designations, conducting large-scale studies on psilocybin, successful financing rounds, and establishing important partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.42%
Tags
management
-
News
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 
Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) reports financial results for Q4 2023, with a cash position of $220.2 million as of December 31, 2023. The company's COMP360 phase 3 pivotal program is progressing, with top-line data expected in Q4 2024 and mid-2025. Teri Loxam appointed as Chief Financial Officer on March 1, 2024. Net loss for 2023 was $118.5 million, with R&D expenses increasing to $87.5 million. Cash and cash equivalents at $220.2 million as of December 31, 2023, with $31.4 million net cash raised in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.98%
Tags
earnings
-
News
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) and Hackensack Meridian Health have announced a research collaboration agreement to inform the delivery model design of investigational COMP360 psilocybin treatment for treatment-resistant depression. The collaboration aims to improve health outcomes and patient experiences. COMP360 is Compass's proprietary formulation of synthetic psilocybin, administered with psychological support. Hackensack Meridian Health, a leading not-for-profit healthcare organization, will leverage its extensive experience in treating depression to inform how new mental health treatments may be accessed by patients in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
News
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) and Greenbrook TMS Inc. (NASDAQ: GBNH) have entered into a three-year research collaboration to explore scalable, commercial delivery models for COMP360 psilocybin treatment upon FDA approval. COMP360 has been designated a 'Breakthrough Therapy' by the FDA for treatment-resistant depression (TRD). The collaboration aims to improve patient care experience and therapist needs, as well as investigate the potential use of digital tools within Greenbrook TMS's care pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.97%
Tags
none
-
News
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) announced positive initial safety findings for investigational COMP360 psilocybin treatment in a phase 2 clinical trial for post-traumatic stress disorder (PTSD). The 24-hour data readout showed that COMP360 was well-tolerated with no serious adverse events. The study is being conducted in the UK and US, with safety and efficacy data expected to be announced in spring 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.87%
Tags
clinical trial
-
News
Compass Pathways appoints Teri Loxam as Chief Financial Officer
Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) has appointed Teri Loxam as Chief Financial Officer (CFO), effective March 2024. Teri brings deep strategic experience from publicly traded companies in the pharmaceutical and biotechnology sectors. She will be based in the company’s New York City office.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
management
News
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) announced the publication of a paper in JAMA Psychiatry demonstrating the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder. The study conducted by Dr. Scott Aaronson at Sheppard Pratt, Baltimore, and funded by Compass, showed that all participants had lower MADRS scores with a mean change from baseline of -24.0 points at week 3, with 12 participants meeting the response criteria and 11 meeting the remission criteria. The study also reported no increase in the suicidality score, no manic symptoms, and no unexpected adverse events or difficulties with the dosing sessions reported throughout the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none
-
News
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) announced the initiation of the UK component of its phase 3 program of investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD). The research will take place in multiple sites in the UK, including at the Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. The phase 3 program is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted and follows promising results from Compass’s phase 2b study of COMP360 psilocybin treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
clinical trial
-
News
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
COMPASS Pathways reports financial results for Q3 2023, with a cash position of $248.0 million as of September 30, 2023. The COMP360 phase 3 program is ongoing, and top-line data for COMP005 is expected in summer 2024. The company also expects top-line data for its phase 2 study in PTSD by the end of this year. COMPASS secured up to $285 million in private placement financing. The CEO expressed confidence in the clinical programs and pre-commercial work for a potential new drug application filing with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
earnings
News
COMPASS Pathways announces CFO transition
Rhea-AI Summary
COMPASS Pathways announces CFO departure and appointment of interim CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
none
Stock CMPS logo
Compass Pathways Plc

Nasdaq:CMPS

CMPS Rankings

#2831 Ranked by Market Cap
#4661 Ranked by Stock Gains
N/A Ranked by Dividends

CMPS Stock Data

591.85M
36.86M
28.37%
39.91%
4.58%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
London

About CMPS

compass pathways is a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health. our first major initiative is developing psilocybin therapy through late-stage clinical trials in the eu and us for patients with treatment-resistant depression. we are developing psychoactive care pathways based on advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.